Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Лечебное дело
2015 / N 4

Гастроэзофагеальная рефлюксная болезнь: формы заболевания и особенности их лечения (библиография)
С.В. Морозов, Ю.А. Кучерявый

1. Peery A.F., Dellon E.S., Lund J. et al. Burden of gastrointestinal disease in the United States: 2012 update // Gastroenterology. 2012. V. 143. P. 1179–1187.
2. Исаков В.А., Морозов С.В., Ставраки Е.С., Комаров Р.С. Анализ Распространенности Изжоги: нАциональное эпиДемиологическое исследоваНие взрослого городского нАселения (АРИАДНА) // Экспер. и клин. гастроэнтерол. 2008. № 1. C. 20–30.
3. Vakil N., van ZantenS.V., Kahrilas P. et al.; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus // Am. J. Gastroenterol. 2006. V. 101. P. 1900–1920.
4. Pace F., Bianchi Porro G. Gastroesophageal reflux disease: a typical spectrumdisease (a new conceptual framework is not needed) // Am. J. Gastroenterol. 2004. V. 99. P. 946–949.
5. Pace F., Bollani S., Molteni P., Bianchi Porro G. Natural history ofgastro-oesophageal reflux disease without oesophagitis (NERD) – a reappraisal 10years on // Dig. Liver Dis. 2004. V. 36. P. 111–115.
6. Fass R. Distinct phenotypic presentations of gastroesophageal reflux disease: a new view of the natural history // Dig Dis. 2004. V. 22. P. 100–107.
7. Jankowski J.A., Provenzale D., Moayyedi P. Esophageal adenocarcinoma arising from Barrett’s metaplasia has regional variations in the west // Gastroenterology. 2002. V. 122. P. 588–590.
8. Dent J., Brun J., Fendrick A.M. et al. An evidence-basedappraisal of reflux disease management – the Genval workshop report // Gut. 1999. V. 44. Suppl. 2. P. S1–16.
9. Malfertheiner P., Nocon M., Vieth M. et al. Evolution of gastro-oesophagealreflux disease over 5 years under routine medical care – the ProGERD study // Aliment. Pharmacol. Ther. 2012. V. 35. P. 154–164.
10. Locke G.R. 3rd, Talley N.J., Fett S.L. et al. Prevalence and clinical spectrum of gastroesophageal reflux: apopulation-based study in Olmsted County, Minnesota // Gastroenterology. 1997. V. 112. P. 1448–1456.
11. Fitzgerald R.C., Onwuegbusi B.A., Bajaj-Elliott M. et al. Diversity in the oesophageal phenotypic response togastro-oesophageal reflux: immunological determinants // Gut. 2002. V. 50. P. 451–459.
12. Hartmann D., Kudis V., Jakobs R. et al. Course oferosive gastresophageal reflux disease (ERD) – a prospective examination under therapeutic daily life conditionswith a mean follow-up of 6,5 years // Z. Gastroenterol. 2006. V. 44. P. 1039–1042.
13. Sontag S.J., Sonnenberg A., Schnell T.G. et al. The long-term natural history of gastresophageal reflux disease // J. Clin. Gastroenterol. 2006. V. 40. P. 398–404.
14. Isolauri J., Luostarinen M., Isolauri E. et al. Natural course of gastresophageal reflux disease: 17–22 year follow-up of 60 patients // Am. J. Gastroenterol. 1997. V. 92. P. 37–41.
15. Lee Y.C., Yen A.M., Tai J.J. et al. The effect of metabolic risk factors on the natural course of gastro-oesophageal reflux disease // Gut. 2009. V. 58. P. 174–181.
16. Fullard M., Kang J.Y., Neild P. et al. Systematic review: does gastro-oesophageal reflux disease progress? // Aliment. Pharmacol. Ther. 2006. V. 24. P. 33–45.
17. Ho K.Y., Kang J.Y. Reflux esophagitis patients in Singapore havemotor and acid exposure abnormalities similar to patients in the Western hemisphere // Am. J. Gastroenterol. 1999. V. 94. P. 1186–1119.
18. Martinez S.D., Malagon I., Garewal H.S., Fass R. Non-erosive reflux disease (NERD) – is it really just a mild form of gastroesophageal reflux disease (GERD) [abstract]? // Gastroenterology. 2001. V. 120. Suppl. 1. P. A424.
19. Frootan M., Choobtashani S., Azargashb E. et al. Non-erosive reflux disease compared with erosive esophagitis with regards to acid reflux and symptom patterns // Turk. J. Gastroenterol. 2011. V. 22. P. 464–471.
20. Smout A.J.P.M. Endoscopy-negative acid reflux disease // Aliment. Pharmacol. Ther. 1997. V. 11. Suppl. 2. P. 81–85.
21. Orlando R.C. Review article: oesophageal mucosal resistance // Aliment. Pharmacol. Ther. 1998. V. 12. P. 191–197.
22. Кукушкина М.Д., Морозов С.В., Исаков В.А. Роль комбинированной 24-часовой рH-импедансометрии пищевода в диагностике различных клинических форм гастроэзофагеальной рефлюксной болезни // Экспер. и клин. гастроэнтерол. 2012. № 7. С. 91–96.
23. Knowles C.H., Aziz Q. Visceral hypersensitivity in non-erosive reflux disease // Gut. 2008. V. 57. P. 674–683.
24. Miwa H., Minoo T., Hojo M. et al. Oesophageal hypersensitivity in Japanese patients with non-erosive gastro-oesophageal reflux diseases // Aliment. Pharmacol. Ther. 2004. V. 20. Suppl. 1. P. 112–117.
25. Nagahara A., Miwa H., Minoo T. et al. Increased esophageal sensitivity to acid and saline in patients with nonerosive gastro-esophageal reflux disease // J. Clin. Gastroenterol. 2006. V. 40. P. 891–895.
26. Shapiro M., Green C., Bautista J.M. et al. Functional heartburn patients demonstrate traits of functional bowel disorder but lack a uniform increase of chemoreceptor sensitivity to acid // Am. J. Gastroenterol. 2006. V. 101. P. 1084–1091.
27. Thoua N.M., Khoo D., Kalantzis C., Emmanuel A.V. Acid-related oesophageal sensitivity, not dysmotility, differentiates subgroups of patients with non-erosive reflux disease // Aliment. Pharmacol. Ther. 2008. V. 27. P. 396–403.
28. Reddy H., Staahl C., Arendt-Nielsen L. et al. Sensory and biomechanical properties of theesophagus in non-erosive reflux disease // Scand. J. Gastroenterol. 2007. V. 42. P. 432–440.
29. Trimble K.C., Pryde A., Heading R.C. Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD // Gut. 1995. V. 37. P. 7–12.
30. Bhat Y.M., Bielefeldt K. Capsaicin receptor (TRPV1) and non-erosive reflux disease // Eur. J. Gastroenterol. Hepatol. 2006. V. 18. P. 263–270.
31. Sarkar S., Hobson A.R., Hughes A. et al. The prostaglandin E2 receptor-1 (EP-1) mediates acid-induced visceral pain hypersensitivity in humans // Gastroenterology. 2003. V. 124. P. 18–25.
32. Anand P., Aziz Q., Willert R., van Oudenhove L. Peripheral andcentral mechanisms of visceral sensitization in man // Neurogastroenterol. Motil. 2007. V. 19. P. 29–46.
33. Fass R., Naliboff B.D., Fass S.S. et al. The effect of auditory stress on perception of intraesophageal acid in patients with GERD // Gastroenterology. 2008. V. 134. P. 696–705.
34. Dent J. Microscopic esophageal mucosal injury in non erosive reflux disease // Clin. Gastroenterol. Hepatol. 2007. V. 5. P. 4–16.
35. Mastracci L., Grillo F., Zentilin P. et al. Cell proliferation of squamousepithelium in gastro-oesophageal reflux disease: correlationswith clinical, endoscopic and morphological data // Aliment. Pharmacol. Ther. 2007. V. 25. P. 637–645.
36. Schey R., Dickman R., Parthasarathy S. et al. Sleep deprivation is hyperalgesicin patients with gastroesophageal reflux disease // Gastroenterology. 2007. V. 133. P. 1787–1795.
37. Ang D., Sifrim D., Tack J. Mechanisms of heartburn // Nat. Clin. Pract. Gastroenterol. Hepatol. 2008. V. 5. P. 383–392.
38. Yang X.J., Jiang H.M., Hou X.H., Song J. Anxiety and depression in patients with gastroesophageal reflux disease and their effect on quality of life // World J. Gastroenterol. 2015. V. 21. P. 4302–4309.
39. Sanna L., Stuart A.L, Berk M. et al. Gastrooesophageal reflux disease (GORD)-related symptoms and its association with mood and anxiety disorders and psychological symptomology: a population-based study in women // BMC Psychiatry. 2013. V. 13. V. 194.
40. Lew E.A. Review article: pharmacokinetic concerns in the selection of anti-ulcer therapy // Aliment. Pharmacol. Ther. 1999. V. 13. Suppl. 5. P. 11–16.
41. Massoomi F., Savage J., Destache C.J. Omeprazole: a comprehensive review // Pharmacotherapy. 1993. V. 13. P. 46–59.
42. Исаков В.А. Ингибиторы протонного насоса: их свойства и применение в гастроэнтерологии. М.: Академкнига, 2001.
43. Abelo A., Andersson T.B., Bredberg U. et al. Stereoselective metabolism by human liver CYP enzymes of a substituted benzimidazole // Drug Metab. Dispos. 2000. V. 1. P. 58–64.
44. Andersson T. Pharmacokinetics, metabolism and interactions of acid inhibitors. Focus on omeprazole and pantoprazole // Clin. Pharmacokinet. 1996. V. 31. P. 9–28.
45. Andersson T., Rohss K., Hassan-Alin M. Pharmacokinetics and dose-response relationship of esomeprazole // Gastroenterology. 2000. V. 118. Suppl. 2. P. A2110.
46. Andersson T., Hassan-Alin M., Hasselgren G. et al. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole // Clin. Pharmacokinet. 2001. V. 40. P. 411–426.
47. Richter J.E., Kahrilas P.J., Johanson J. et al.; Esomeprazole Study Investigators. Efficacy and safety ofesomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial // Am. J. Gastroenterol. 2001. V. 96. P. 656–665.
48. De Morais S.M., Goldstein J.A., Xie H.G. et al. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population // Clin. Pharmacol. Ther. 1995. V. 58. P. 401–411.
49. Ishizaki T., Sohn D.R., Kobayashi K. et al. Interethnic differences in omeprazole metabolism in the two S-mephenitoin hydroxylation phenotypes studied in Caucasians and Orientals // Ther. Drug Monit. 1994. V. 16. P. 214–215.
50. Kubota T., Chiba K., Ishizaki T. Genotyping of S-mephenytoin polymorphism in an extended Japanese population // Clin. Pharmacol. Ther. 1996. V. 60. P. 661–666.
51. Marinac J.S., Balian J.D., Foxworth J.W. et al. Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype // Clin. Pharmacol. Ther. 1996. V. 60. P. 138–144.
52. Masimirembwa C., Bertillson L., Johansson A. et al. Phenotyping and genotyping of S-mephenytoin hydroxilase (cytochrome p450 2C19) in a Shona population of Zimbabwe // Clin. Pharmacol. Ther. 1995. V. 57. P. 656–661.
53. Roh H.K., Dahl M.L., Tybring G. et al. CYP 2C19 genotype and phenotype determined by omeprazole in Korean population // Pharmacogenetics. 1996. V. 6. P. 547–551.
54. Xie H.G., Kim R.B., Stein C.M. et al. Genetic polymorphism of (S) – mephenytoin 4’-hydroxylation in populations of African descent // Br. J. Clin. Pharmacol. 1999. V. 48. P. 402–408.
55. Xiao Z.S., Goldstein J.A., Xie H.G. et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenitoin phenotype in Chinese Shan and Bai populations and identification of a new rare CYP2C19 mutant allele // J. Pharmacol. Exp. Ther. 1997. V. 281. P. 604–609.
56. Морозов С.В., Исаков В.А., Цодикова О.М. и др. Полиморфизм гена СYP2С19 у больных гастроэзофагеальной рефлюксной болезнью // Клин. фармакол. и тер. 2004. № 1. С. 49–52.
57. Bell N.J.V., Burget D.L., Howden C.W. et al. Appropriate acid suppression for the management of gastro-esophageal reflux disease // Digestion. 1992. V. 51. Suppl. 1. P. 59–67.
58. Bell N.J.V., Hunt R.H. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease // Gut. 1992. V. 33. P. 118–124.
59. Miner Jr. P., Katz P.O., Chen Y., Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way cross-over study // Am. J. Gastroenterol. 2003. V. 98. P. 2616–2620.
60. Исаков В.А., Морозов С.В., Цодикова О.М. и др. Сравнительная эффективность антисекреторного действия рабепразола и эзомепразола у лиц, быстро метаболизирующих ингибиторы протонного насоса // Экспер. и клин. гастроэнтерол. 2003. № 6. С. 58–63.
61. Морозов С.В., Исаков В.А., Цодикова О.М. Влияние эзомепразола и рабепразола на закисление пищевода у больных гастроэзофагеальнойрефлюксной болезнью, интенсивно метаболизирующих ингибиторы протонного насоса // Тер. архив. 2005. № 2. С. 21–25.
62. Dean B.B., Gano A.D. Jr., Knight K. et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease // Clin. Gastroenterol. Hepatol. 2004. V. 2. P. 656–664.
63. Lind T., Havelund T., Carlsson R. et al. Heartburn without oesophagitis:efficacy of omeprazole therapy and features determining therapeutic response // Scand. J. Gastroenterol. 1997. V. 32. P. 974–979.
64. Edwards S.J., Lind T., Lundell L., DAS R. Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis- a mixed treatment comparison of randomized controlled trials // Aliment. Pharmacol. Ther. 2009. V. 30. P. 547–556.
65. Bytzer P., Blum A., De Herdt D., Dubois D.; Trial Investigators. Six-month trial ofon-demand rabeprazole 10 mg maintains symptom relief in patientswith non-erosive reflux disease // Aliment. Pharmacol. Ther. 2004. V. 20. P. 181–188.
66. Juul-Hansen P., Rydning A. On-demand requirements in patient with endoscopy-negative GERD: H2-blocker versus PPI // Aliment. Pharmacol. Ther. 2009. V. 29. P. 207–212.
67. Wiklund I., Bardhan K.D., Muller-Lissner S. et al. Quality of life during acute and intermittent treatment of gastro-oesophageal refluxdisease with omeprazole compared with ranitidine. Results froma multicentre clinical trial. The European Study Group. // Ital. J. Gastroenterol. Hepatol. 1998. V. 30. P. 19–27.
68. Gerson L.B., Robbins A.S., Garbert A. et al. A cost-effectiveness analysis of prescribing strategies in themanagement of gastroesophageal reflux disease // Am. J. Gastroenterol. 2000. V. 95. P. 395–407.
69. Talley N.J., Venables T.L., Green J.R. et al. Esomeprazole 40 mg and 20 mg isefficacious in the long-term management of patients with endoscopy-negativegastro-oesophageal reflux disease: a placebo-controlled trial of on-demandtherapy for 6 months // Eur. J. Gastroenterol. Hepatol. 2002. V. 14. P. 857–863.
70. Escourrou J., Deprez P., Saggioro A. et al. Maintenancetherapy with pantoprazole 20 mg prevents relapse of reflux oesophagitis // Aliment Pharmacol. Ther. 1999. V. 13. P. 1481–1491.
71. Pace F., Tonini M., Pallotta S. et al. Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken 'on-demand' // Aliment. Pharmacol. Ther. 2007. V. 26. P. 195–204.
72. Sjöstedt S., Befrits R., Sylvan A. et al. Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis // Aliment. Pharmacol. Ther. 2005. V. 22. P. 183–191.
73. Johnson D.A., Benjamin S.B., Vakil N.B. et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety // Am. J. Gastroenterol. 2001. V. 96. P. 27–34.
74. Labenz J., Armstrong D., Leodolter A., Baldycheva I. Management of reflux esophagitis: does the choice of proton pump inhibitor matter? // Int. J. Clin. Pract. 2015. V. 69. P. 796–801.
  

[ Содержание выпуска N 4 | Выпуски журнала | Список журналов ]